There are currently 1093 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate of the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle
Recruiting
The purpose of this study is to evaluate opioid dose effects on the ability of the diaphragm muscle to generate higher force behaviors.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/15/2023
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Respiratory Function Loss, Respiratory Complication
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Recruiting
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
Recruiting
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Recruiting
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
Male
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Multiple Myeloma
Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
Recruiting
The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
08/08/2023
Locations: GSK Investigational Site, Rochester, Minnesota
Conditions: Hypereosinophilic Syndrome
Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain
Recruiting
The study utilizes a 3-arm placebo-controlled RCT to study the effectiveness of ketamine in reducing chronic post-mastectomy pain. Participants randomized to the first arm will receive a 0.35 mg/kg dose after induction, followed by a 0.25 mg/kg/hr infusion during surgery (up to a maximum of 6 hours) and continued for 2 hours postoperatively. Participants in the second arm will receive a single dose of 0.6 mg/kg of ketamine in the post-anesthesia care unit, and the final group will serve as the c... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Chronic Postsurgical Pain
Evaluation of ECG Transmission and AI Models Using Apple Watch ECGs and Symptoms Data Collected Using a Mayo iPhone App
Recruiting
The purpose of the study is to determine if the Electrocardiograms (ECGs) and symptoms data obtained from an Apple Watch and transmitted to Mayo Clinic are of sufficient quality to guide a person's care.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Heart Failure, Arrhythmias, Cardiac, Health Care Utilization
Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator
Recruiting
Evaluate data accuracy of cardiac acoustic biomarkers (CABs) recorded by the Wearable Cardioverter Defibrillator (WCD) as compared to the AUDICOR AM acoustic cardiography recorder.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: MAYO Clinic, Rochester, Minnesota
Conditions: Heart Failure
NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis
Recruiting
The Researchers are trying to compare two different types of intraarticular injections (injection in the joint) for treating the symptoms of moderate to advanced basilar thumb arthritis. One injection is ketorolac (an NSAID) and the other is triamcinolone (a corticosteroid).
Gender:
All
Ages:
40 years and above
Trial Updated:
08/07/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Thumb Osteoarthritis
Treatment of an Inherited Ventricular Arrhythmia
Recruiting
The goal of the proposed project is to determine the safety and tolerability as well as the preliminary efficacy of a novel small molecule drug, S48168 (ARM210), for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1). This disease is associated with fatal changes in heart rhythms leading to sudden death with exercise or excessive excitement. It is due to mutations in the Ryanodine Receptor calcium release channel, which cause leaky channels leading to the disease. S48... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
08/03/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia Type 1